Salarius Pharmaceuticals, Inc.(SLRX)Earnings, Financials & Key Ratios
SLRX•NASDAQ
Price updated May 1, 2026
AboutSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$6M+55.5%
- Net Income-$6M+55.5%
- EPS (Diluted)-86.85-152268.4%
- ROE-164.02%-2.5%
SLRX Key Insights
Salarius Pharmaceuticals, Inc. (SLRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 70.5% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SLRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLRX Price & Volume
Salarius Pharmaceuticals, Inc. (SLRX) stock price & volume — 10-year historical chart
Loading chart...
SLRX Growth Metrics
Salarius Pharmaceuticals, Inc. (SLRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.9%
Return on Capital
10 Years-94.69%
5 Years-110.52%
3 Years-154.31%
Last Year-168.68%
SLRX Peer Comparison
Salarius Pharmaceuticals, Inc. (SLRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KROS | 340.78M | 10.65 | 4.63 | 67.75% | -256.6% | -17.04% | 0.06 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 SYRS | 10.73K | 0.00 | -0.00 | -33.23% | -253.41% | -27.47% | 3.73 |
Compare SLRX vs Peers
Salarius Pharmaceuticals, Inc. (SLRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLRX Income Statement
Salarius Pharmaceuticals, Inc. (SLRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.01M | 1.27M | 838.14K | 3.47M | 5.23M | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | 26.11% | -34.24% | 313.42% | 51.03% | -100% | - | - | - | - |
Cost of Goods Sold | 662.75K | 506.53K | 430.75K | 0 | 0 | 0 | 0 | 0 | 0 | 1.11K |
COGS % of Revenue | 65.58% | 39.74% | 51.39% | - | - | - | - | - | - | - |
Gross Profit | 347.92K▲ 0% | 767.97K▲ 120.7% | 407.39K▼ 47.0% | 3.47M▲ 750.5% | 5.23M▲ 51.0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.11K▲ 0% |
Gross Margin % | 34.42% | 60.26% | 48.61% | 100% | 100% | - | - | - | - | - |
Gross Profit Growth % | 797.49% | 120.73% | -46.95% | 750.55% | 51.03% | -100% | - | - | - | - |
Operating Expenses | 40.23M | 35.49M | 22.48M | 11.73M | 13.02M | 12.81M | 31.84M | 12.89M | 5.73M | 5.07M |
OpEx % of Revenue | 3980.97% | 2784.91% | 2682.32% | 338.53% | 248.78% | - | - | - | - | - |
Selling, General & Admin | 19.86M | 18.5M | 10.57M | 7.71M | 6.11M | 6.1M | 7.14M | 5.72M | 4.96M | 4.64M |
SG&A % of Revenue | 1964.65% | 1451.84% | 1261.52% | 222.54% | 116.67% | - | - | - | - | - |
Research & Development | 20.38M | 16.99M | 11.91M | 4.02M | 6.91M | 8.55M | 15.84M | 7.17M | 770.03K | 429.08K |
R&D % of Revenue | 2016.32% | 1333.07% | 1420.8% | 115.99% | 132.11% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1.84M | 8.87M | 0 | 0 | 0 |
Operating Income | -39.89M▲ 0% | -34.73M▲ 12.9% | -22.07M▲ 36.4% | -8.27M▲ 62.6% | -7.79M▲ 5.8% | -12.81M▼ 64.6% | -31.84M▼ 148.5% | -12.89M▲ 59.5% | -5.73M▲ 55.5% | -5.07M▲ 0% |
Operating Margin % | -3946.54% | -2724.65% | -2633.71% | -238.53% | -148.78% | - | - | - | - | - |
Operating Income Growth % | -36.54% | 12.94% | 36.43% | 62.56% | 5.79% | -64.56% | -148.51% | 59.5% | 55.53% | - |
EBITDA | -39.61M | -34.4M | -21.85M | -8.14M | -7.77M | -12.79M | -31.83M | -12.88M | -5.73M | -5.06M |
EBITDA Margin % | -3919.11% | -2699.18% | -2606.49% | -234.85% | -148.44% | - | - | - | - | - |
EBITDA Growth % | -35.82% | 13.15% | 36.5% | 62.75% | 4.54% | -64.69% | -148.83% | 59.53% | 55.53% | 2.84% |
D&A (Non-Cash Add-back) | 277.23K | 324.55K | 228.16K | 127.41K | 18.06K | 19.18K | 6.68K | 10.05K | 4.42K | 4.42K |
EBIT | -39.89M | -34.73M | -22.07M | -8.26M | -7.61M | -12.81M | -22.98M | -12.89M | -5.73M | -5.05M |
Net Interest Income | 393.11K | 291.96K | 152.01K | 15.65K | -3.05K | 0 | 219 | 352.25K | 158.54K | 63.34K |
Interest Income | 393.11K | 291.96K | 152.01K | 15.65K | 0 | 0 | 219 | 352.25K | 158.54K | 63.34K |
Interest Expense | 0 | 0 | 0 | 0 | 3.05K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 393.11K | 291.96K | 152.01K | 1.33M | 434.09K | 44.69K | 233.18K | 352.25K | 158.54K | 63.34K |
Pretax Income | -39.49M▲ 0% | -34.43M▲ 12.8% | -21.92M▲ 36.3% | -6.94M▲ 68.4% | -7.35M▼ 6.0% | -12.77M▼ 73.7% | -31.61M▼ 147.6% | -12.54M▲ 60.3% | -5.58M▲ 55.5% | -5M▲ 0% |
Pretax Margin % | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -39.49M▲ 0% | -34.43M▲ 12.8% | -21.92M▲ 36.3% | -6.94M▲ 68.4% | -7.35M▼ 6.0% | -12.77M▼ 73.7% | -31.61M▼ 147.6% | -12.54M▲ 60.3% | -5.58M▲ 55.5% | -5M▲ 0% |
Net Margin % | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
Net Income Growth % | -35.52% | 12.81% | 36.33% | 68.36% | -6% | -73.66% | -147.55% | 60.32% | 55.55% | -0.22% |
Net Income (Continuing) | -39.49M | -34.43M | -21.92M | -6.94M | -7.35M | -12.77M | -31.61M | -12.54M | -5.58M | -5M |
Discontinued Operations | 0 | 0 | 0 | 1.83K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -182250.00▲ 0% | -149250.00▲ 18.1% | -91500.00▲ 38.7% | -6360.00▲ 93.0% | -1500.00▲ 76.4% | -930.00▲ 38.0% | -221.55▲ 76.2% | -0.06▲ 100.0% | -86.85▼ 152268.4% | -10.39▲ 0% |
EPS Growth % | -836.11% | 18.11% | 38.69% | 93.05% | 76.42% | 38% | 76.18% | 99.97% | -152268.42% | 61.9% |
EPS (Basic) | -182250.00 | -149250.00 | -91500.00 | -6360.00 | -1500.00 | -930.00 | -221.55 | -0.06 | -86.85 | - |
Diluted Shares Outstanding | 1.09M | 1.16M | 1.21M | 1.09K | 5.22K | 13.86K | 142.34K | 218.73K | 64.47K | 481.59K |
Basic Shares Outstanding | 1.09M | 1.16M | 1.21M | 1.09K | 5.22K | 13.8K | 142.34K | 218.73K | 64.47K | 481.59K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SLRX Balance Sheet
Salarius Pharmaceuticals, Inc. (SLRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 62.47M | 34.54M | 10.32M | 4.69M | 15.8M | 30.16M | 14.52M | 6.52M | 2.99M | 6.06M |
Cash & Short-Term Investments | 61.07M | 33.32M | 9.83M | 3.74M | 11.12M | 29.21M | 12.11M | 5.9M | 2.43M | 4.81M |
Cash Only | 22.42M | 19.19M | 9.83M | 3.74M | 11.12M | 29.21M | 12.11M | 5.9M | 2.43M | 4.81M |
Short-Term Investments | 38.66M | 14.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 12.18K | 10.38K | 9.94K | 0 | 3.86M | 0 | 1.61M | 0 | 0 | 0 |
Days Sales Outstanding | 4.4 | 2.97 | 4.33 | - | 268.94 | - | - | - | - | - |
Inventory | 454.13K | 431.89K | 186.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 250.11 | 311.22 | 158.39 | - | - | - | - | - | - | - |
Other Current Assets | 0 | 767.56K | 249.09K | 0 | 137.78K | 172.99K | 167.58K | 151.27K | 221.58K | 1.26M |
Total Non-Current Assets | 747.71K | 457.63K | 74.46K | 9.2M | 9.14M | 10.67M | 130.5K | 66.85K | 35.41K | 32.09K |
Property, Plant & Equipment | 556.32K | 331.04K | 74K | 25.02K | 22.64K | 7.88K | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | 1.82x | 3.85x | 11.33x | 138.51x | 231.16x | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 8.87M | 8.87M | 8.87M | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 66.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 1.61M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 191.4K | 60.2K | 460 | 308.67K | 247.11K | 185.99K | 130.5K | 66.85K | 35.41K | 32.09K |
Total Assets | 63.21M▲ 0% | 34.99M▼ 44.6% | 10.39M▼ 70.3% | 13.89M▲ 33.7% | 24.93M▲ 79.4% | 40.83M▲ 63.8% | 14.65M▼ 64.1% | 6.59M▼ 55.0% | 3.02M▼ 54.1% | 6.1M▲ 0% |
Asset Turnover | 0.02x | 0.04x | 0.08x | 0.25x | 0.21x | - | - | - | - | 0.00x |
Asset Growth % | -33.51% | -44.64% | -70.31% | 33.73% | 79.44% | 63.78% | -64.12% | -55.04% | -54.1% | -109.02% |
Total Current Liabilities | 3.89M | 5.85M | 5.02M | 3.31M | 2.77M | 2.11M | 4.27M | 1.3M | 1.51M | 1.1M |
Accounts Payable | 1.19M | 2M | 342.53K | 1.79M | 1.85M | 1.54M | 2.86M | 602.85K | 936.99K | 1.1M |
Days Payables Outstanding | 656.58 | 1.44K | 290.25 | - | - | - | - | - | - | 412.01K |
Short-Term Debt | 0 | 0 | 0 | 502.33K | 477.03K | 0 | 0 | 289.64K | 221.87K | 0 |
Deferred Revenue (Current) | 88K | 72.19K | 0 | 541.7K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.16M | 2.9M | 3.91M | 317.76K | 59.21K | 0 | 0 | 0 | 0 | 0 |
Current Ratio | 16.06x | 5.91x | 2.06x | 1.42x | 5.70x | 14.29x | 3.40x | 5.02x | 1.98x | 5.49x |
Quick Ratio | 15.94x | 5.83x | 2.02x | 1.42x | 5.70x | 14.29x | 3.40x | 5.02x | 1.98x | 5.49x |
Cash Conversion Cycle | -402.07 | -1.13K | -127.53 | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 8.4K | 39.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 744.78K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8.4K | 39.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 744.78K |
Total Liabilities | 3.9M | 5.89M | 1.11M | 3.31M | 2.77M | 2.11M | 4.27M | 1.3M | 1.51M | 1.85M |
Total Debt | 0 | 0 | 0 | 502.33K | 477.03K | 0 | 0 | 289.64K | 221.87K | 0 |
Net Debt | -22.42M | -19.19M | -9.83M | -3.24M | -10.64M | -29.21M | -12.11M | -5.61M | -2.21M | -4.81M |
Debt / Equity | - | - | - | 0.05x | 0.02x | - | - | 0.05x | 0.15x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.95x |
Interest Coverage | - | - | - | - | -2555.41x | - | - | - | - | - |
Total Equity | 59.32M▲ 0% | 29.11M▼ 50.9% | 9.28M▼ 68.1% | 10.58M▲ 14.0% | 22.16M▲ 109.4% | 38.72M▲ 74.7% | 10.38M▼ 73.2% | 5.29M▼ 49.1% | 1.51M▼ 71.4% | 4.25M▲ 0% |
Equity Growth % | -35.66% | -50.93% | -68.11% | 13.98% | 109.43% | 74.75% | -73.18% | -49.09% | -71.41% | -259.39% |
Book Value per Share | 54.54 | 25.17 | 7.69 | 9663.05 | 4246.01 | 2794.36 | 72.96 | 24.17 | 23.45 | 8.82 |
Total Shareholders' Equity | 59.32M | 29.11M | 9.28M | 10.58M | 22.16M | 38.72M | 10.38M | 5.29M | 1.51M | 4.25M |
Common Stock | 1.68K | 1.78K | 1.81K | 451 | 2.38K | 4.52K | 225 | 393 | 144 | 94 |
Retained Earnings | -76.65M | -111.08M | -132.96M | -12.08M | -19.43M | -32.2M | -63.81M | -76.35M | -81.92M | -85.46M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.61K | -1.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLRX Cash Flow Statement
Salarius Pharmaceuticals, Inc. (SLRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -32.05M | -27.72M | -23.6M | -11.58M | -10.31M | -10.2M | -17.6M | -12.85M | -4.53M | -4.43M |
Operating CF Margin % | -3171.39% | -2175.14% | -2815.59% | -334.2% | -197.03% | - | - | - | - | - |
Operating CF Growth % | -54.5% | 13.51% | 14.87% | 50.93% | 10.96% | 1.08% | -72.5% | 26.99% | 64.77% | 61.79% |
Net Income | -39.49M | -34.43M | -21.92M | -6.94M | -7.35M | -12.77M | -31.61M | -12.54M | -5.58M | -5M |
Depreciation & Amortization | 277.23K | 324.55K | 228.16K | 127.41K | 18.06K | 19.18K | 6.68K | 10.05K | 4.42K | 4.42K |
Stock-Based Compensation | 6.57M | 4.22M | 1.94M | 751.62K | 319.39K | 559.04K | 796.8K | 524.84K | 273.73K | 130.58K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 19.59K | -66.36K | 31.85K | -1.31M | -258.55K | -44.69K | 10.84M | 130K | 0 | 0 |
Working Capital Changes | 571.22K | 2.23M | -3.88M | -4.21M | -3.04M | 2.03M | 2.37M | -968.33K | 772.29K | 436.54K |
Change in Receivables | 0 | 1.8K | 7.21K | 690 | -3.86M | 2.25M | 0 | 1.48M | 0 | 0 |
Change in Inventory | 0 | 22.24K | 227.98K | 1.17K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 309.44K | 819.36K | -1.66M | -519.28K | -2.78K | -310.66K | 1.31M | -2.26M | 334.14K | 798.33K |
Cash from Investing | -12.24M | 24.49M | 14.12M | 5.61M | -2.6K | 0 | -1.5M | 0 | 0 | -200K |
Capital Expenditures | -559.38K | -113.5K | 0 | 0 | -2.6K | 0 | 0 | -3 | 0 | 0 |
CapEx % of Revenue | 55.35% | 8.91% | - | - | 0.05% | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 5.61M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 5.25K | 5.34K | 4.8K | 0 | 0 | 0 | -1.5M | 3 | 0 | -200K |
Cash from Financing | 22.1K | 2.63K | 118.01K | 3.58M | 17.69M | 28.3M | 1.99M | 6.64M | 1.06M | 6.16M |
Debt Issued (Net) | 0 | 0 | 0 | -417.88K | -974.43K | -477.03K | 0 | -280.92K | -466.5K | -328.85K |
Equity Issued (Net) | 22.1K | 2.63K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 626.24K |
Dividends Paid | 0 | 0 | 0 | -133.59K | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 118.01K | 0 | 3.87M | 1.49M | 0 | 0 | 0 | 5.86M |
Net Change in Cash | -44.27M▲ 0% | -3.23M▲ 92.7% | -9.36M▼ 189.7% | -2.39M▲ 74.4% | 7.38M▲ 408.4% | 18.1M▲ 145.2% | -17.11M▼ 194.5% | -6.21M▲ 63.7% | -3.47M▲ 44.2% | 1.53M▲ 0% |
Free Cash Flow | -32.61M▲ 0% | -27.84M▲ 14.6% | -23.6M▲ 15.2% | -11.58M▲ 50.9% | -10.31M▲ 10.9% | -10.2M▲ 1.1% | -19.1M▼ 87.2% | -12.85M▲ 32.7% | -4.53M▲ 64.8% | -4.43M▲ 0% |
FCF Margin % | -3226.72% | -2184.05% | -2815.59% | -334.2% | -197.08% | - | - | - | - | - |
FCF Growth % | -55.2% | 14.64% | 15.22% | 50.93% | 10.93% | 1.1% | -87.21% | 32.73% | 64.77% | 16.26% |
FCF per Share | -29.98 | -24.07 | -19.55 | -10575.61 | -1976.30 | -736.08 | -134.15 | -58.73 | -70.20 | -9.21 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.81x | 1.08x | 1.67x | 1.40x | 0.80x | 0.56x | 1.02x | 0.81x | 0.89x |
Interest Paid | 0 | 0 | 0 | 9.01K | 8.66K | 1.47K | 0 | 0 | 0 | 285 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLRX Key Ratios
Salarius Pharmaceuticals, Inc. (SLRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -52.13% | -77.88% | -114.21% | -69.84% | -44.91% | -41.94% | -128.73% | -160.07% | -164.02% | -117.81% |
Return on Invested Capital (ROIC) | -95.87% | -111.25% | -353.26% | -182.39% | -61.92% | -91.41% | -613.37% | - | - | 337.01% |
Gross Margin | 34.42% | 60.26% | 48.61% | 100% | 100% | - | - | - | - | - |
Net Margin | -3907.65% | -2701.74% | -2615.57% | -200.18% | -140.49% | - | - | - | - | - |
Debt / Equity | - | - | - | 0.05x | 0.02x | - | - | 0.05x | 0.15x | 0.00x |
Interest Coverage | - | - | - | - | -2555.41x | - | - | - | - | - |
FCF Conversion | 0.81x | 0.81x | 1.08x | 1.67x | 1.40x | 0.80x | 0.56x | 1.02x | 0.81x | 0.89x |
Revenue Growth | - | 26.11% | -34.24% | 313.42% | 51.03% | -100% | - | - | - | - |
Related:SLRX Dividend History·SLRX Revenue History·SLRX Price History·SLRX P/E History·SLRX Financial Ratios·SLRX Institutional Holders
SLRX Frequently Asked Questions
Salarius Pharmaceuticals, Inc. (SLRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Salarius Pharmaceuticals, Inc. (SLRX) grew revenue by 0.0% over the past year. Growth has been modest.
Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.
Dividend & Returns
Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.
Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.